NASDAQ:RNAC Cartesian Therapeutics (RNAC) Stock Price, News & Analysis → Healthcare Takes A Big Step Forward With The Help Of AI (From The Bull Report) (Ad) Free RNAC Stock Alerts $22.00 +0.97 (+4.61%) (As of 04/29/2024 ET) Add Compare Share Share Today's Range$21.00▼$22.5750-Day Range$13.12▼$23.6152-Week Range$11.66▼$42.60Volume162,651 shsAverage Volume47,647 shsMarket Capitalization$118.65 millionP/E RatioN/ADividend YieldN/APrice Target$45.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Cartesian Therapeutics alerts: Email Address Cartesian Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside104.5% Upside$45.00 Price TargetShort InterestBearish45.28% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.81Based on 29 Articles This WeekInsider TradingAcquiring Shares$365,981 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($3.21) to ($3.46) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.40 out of 5 starsMedical Sector489th out of 918 stocksPharmaceutical Preparations Industry217th out of 428 stocks 3.5 Analyst's Opinion Consensus RatingCartesian Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCartesian Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted45.28% of the float of Cartesian Therapeutics has been sold short.Short Interest Ratio / Days to CoverCartesian Therapeutics has a short interest ratio ("days to cover") of 13.3, which indicates bearish sentiment.Change versus previous monthShort interest in Cartesian Therapeutics has recently increased by 117.84%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCartesian Therapeutics does not currently pay a dividend.Dividend GrowthCartesian Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RNAC. Previous Next 3.2 News and Social Media Coverage News SentimentCartesian Therapeutics has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 29 news articles for Cartesian Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 4 people have searched for RNAC on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows11 people have added Cartesian Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 57% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cartesian Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $365,981.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders31.20% of the stock of Cartesian Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.95% of the stock of Cartesian Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Cartesian Therapeutics are expected to decrease in the coming year, from ($3.21) to ($3.46) per share. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About Cartesian Therapeutics Stock (NASDAQ:RNAC)Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.Read More RNAC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RNAC Stock News HeadlinesApril 26, 2024 | americanbankingnews.comLeerink Partnrs Weighs in on Cartesian Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:RNAC)April 26, 2024 | americanbankingnews.comQ1 2024 Earnings Estimate for Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Issued By HC WainwrightApril 29, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)April 25, 2024 | americanbankingnews.comLeerink Partnrs Weighs in on Cartesian Therapeutics, Inc.'s FY2027 Earnings (NASDAQ:RNAC)April 25, 2024 | americanbankingnews.comLeerink Partnrs Reiterates "Outperform" Rating for Cartesian Therapeutics (NASDAQ:RNAC)April 25, 2024 | americanbankingnews.comEquities Analysts Issue Forecasts for Cartesian Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:RNAC)April 24, 2024 | americanbankingnews.comCartesian Therapeutics (NASDAQ:RNAC) Now Covered by Analysts at SVB LeerinkApril 24, 2024 | americanbankingnews.comCartesian Therapeutics (NASDAQ:RNAC) Price Target Increased to $54.00 by Analysts at HC WainwrightApril 29, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)April 23, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cartesian Therapeutics: Promising CAR-T Therapy and Strategic Financial MovesApril 22, 2024 | businesswire.comCartesian Therapeutics to Present at the ASGCT 27th Annual MeetingApril 15, 2024 | msn.comMarinus Pharmaceuticals, Cartesian Therapeutics, Adial Pharmaceuticals among healthcare moversApril 4, 2024 | businesswire.comCartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceApril 4, 2024 | businesswire.comCartesian Therapeutics Announces New Employment Inducement GrantsMarch 28, 2024 | globenewswire.comCartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock SplitMarch 21, 2024 | finance.yahoo.comCartesian Therapeutics Director Acquires 3.2% More StockMarch 18, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cartesian Therapeutics: Neutral Impact of Xork Termination and High Hopes for Descartes-08 TrialMarch 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cartesian Therapeutics Amidst Strong Financial Position and Promising Descartes-08 Clinical TrialsMarch 7, 2024 | finanznachrichten.deCartesian Therapeutics, Inc.: Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdateMarch 7, 2024 | globenewswire.comCartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdateMarch 6, 2024 | finanznachrichten.deCartesian Therapeutics, Inc.: Cartesian Therapeutics Announces New Employment Inducement GrantMarch 6, 2024 | bizjournals.comBiotech moving HQ outside of Montgomery County following mergerMarch 6, 2024 | globenewswire.comCartesian Therapeutics to Participate in Upcoming Investor ConferencesMarch 5, 2024 | finance.yahoo.comCartesian Therapeutics Establishes New Corporate Headquarters and State-of-the-Art mRNA Cell Therapy cGMP Manufacturing Facility in Frederick, MarylandMarch 5, 2024 | globenewswire.comCartesian Therapeutics Announces New Employment Inducement GrantMarch 5, 2024 | globenewswire.comCartesian Therapeutics Establishes New Corporate Headquarters and State-of-the-Art mRNA Cell Therapy cGMP Manufacturing Facility in Frederick, MarylandFebruary 16, 2024 | finance.yahoo.comCartesian Therapeutics, Inc. (RNAC)See More Headlines Receive RNAC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cartesian Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today4/29/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RNAC Previous SymbolNASDAQ:RNAC CUSIPN/A CIK1453687 Webselectabio.com Phone617-923-1400Fax617-924-3454Employees37Year FoundedN/APrice Target and Rating Average Stock Price Target$45.00 High Stock Price Target$54.00 Low Stock Price Target$39.00 Potential Upside/Downside+114.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-219,710,000.00 Net Margins-845.01% Pretax Margin-917.97% Return on Equity-58.21% Return on Assets-27.22% Debt Debt-to-Equity RatioN/A Current Ratio1.33 Quick Ratio1.33 Sales & Book Value Annual Sales$26 million Price / Sales4.36 Cash FlowN/A Price / Cash FlowN/A Book Value($85.17) per share Price / Book-0.25Miscellaneous Outstanding Shares5,390,000Free Float3,710,000Market Cap$113.35 million OptionableOptionable Beta0.57 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Carsten Brunn Ph.D. (Age 52)President, CEO & Director Mr. Blaine T. Davis (Age 49)Chief Financial Officer Dr. Metin Kurtoglu M.D. (Age 45)Ph.D., Chief Operating Officer Yi Zhang Ph.D.Senior Director of TechnologyDr. Chris Jewell Ph.D. (Age 42)Chief Scientific Officer Mr. Matthew Bartholomae J.D.General Counsel & SecretaryDr. Milos Miljkovic M.D. (Age 40)Ph.D., Chief Medical Officer More ExecutivesKey CompetitorsRelmada TherapeuticsNASDAQ:RLMDNuvectis PharmaNASDAQ:NVCTSocietal CDMONASDAQ:SCTLEliem TherapeuticsNASDAQ:ELYMImmunicNASDAQ:IMUXView All CompetitorsInsiders & InstitutionsHall Laurie J TrusteeBought 52,775 shares on 4/23/2024Ownership: 0.979%Timothy A SpringerBought 634 shares on 3/18/2024Total: $11,412.00 ($18.00/share)Timothy A SpringerBought 21,612 shares on 3/14/2024Total: $350,114.40 ($16.20/share)Timothy A SpringerBought 40 shares on 3/11/2024Total: $780.00 ($19.50/share)Timothy A SpringerBought 160 shares on 3/8/2024Total: $3,168.00 ($19.80/share)View All Insider TransactionsView All Institutional Transactions RNAC Stock Analysis - Frequently Asked Questions Should I buy or sell Cartesian Therapeutics stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cartesian Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RNAC shares. View RNAC analyst ratings or view top-rated stocks. What is Cartesian Therapeutics' stock price target for 2024? 4 brokers have issued 1-year target prices for Cartesian Therapeutics' shares. Their RNAC share price targets range from $39.00 to $54.00. On average, they predict the company's stock price to reach $45.00 in the next year. This suggests a possible upside of 104.5% from the stock's current price. View analysts price targets for RNAC or view top-rated stocks among Wall Street analysts. How have RNAC shares performed in 2024? Cartesian Therapeutics' stock was trading at $20.6820 on January 1st, 2024. Since then, RNAC shares have increased by 6.4% and is now trading at $22.00. View the best growth stocks for 2024 here. Are investors shorting Cartesian Therapeutics? Cartesian Therapeutics saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 638,500 shares, an increase of 117.8% from the March 31st total of 293,100 shares. Based on an average daily trading volume, of 48,000 shares, the days-to-cover ratio is presently 13.3 days. Approximately 45.3% of the company's stock are short sold. View Cartesian Therapeutics' Short Interest. When is Cartesian Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our RNAC earnings forecast. How were Cartesian Therapeutics' earnings last quarter? Cartesian Therapeutics, Inc. (NASDAQ:RNAC) posted its earnings results on Thursday, March, 7th. The company reported ($2.40) earnings per share for the quarter, missing the consensus estimate of ($0.30) by $2.10. The company earned $8.27 million during the quarter. Cartesian Therapeutics had a negative net margin of 845.01% and a negative trailing twelve-month return on equity of 58.21%. When did Cartesian Therapeutics' stock split? Shares of Cartesian Therapeutics reverse split on Friday, April 5th 2024. The 1-30 reverse split was announced on Friday, April 5th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. Who are Cartesian Therapeutics' major shareholders? Cartesian Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Hall Laurie J Trustee (0.98%). View institutional ownership trends. How do I buy shares of Cartesian Therapeutics? Shares of RNAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RNAC) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithElon Musk Secret Crypto Plot ExposedCrypto 101 MediaThe AI stock to buy right nowStockEarningsWhy Big Pharma is Investing Billions in This BiotechBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cartesian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
